Lyell Immunopharma

LYELNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$360.459 M

$14.71 +3.52%

Close of 7 Aug 2026

Revenue

$36.0K

#3637 by revenue

Earnings

-$274.4M

Loss-making

Shares outstanding

24,505,141

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations — ranked by market cap

All 501 →

#226Prelude TherapeuticsPRLD$390.3M
#227DiaMedica TherapeuticsDMAC$363.7M
#228Lyell ImmunopharmaLYEL$360.5M
#229Foghorn TherapeuticsFHTX$356.4M
#230Galectin TherapeuticsGALT$347.9M

Where these numbers come from

Share counts and financials for Lyell Immunopharma are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.